Health News Releases

  • Today December 17
Early Phase Oncology Infographic
December 16, 15:30
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology - Clinical Research Landscape and CRO
December 14, 14:05
Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that Tahoe Therapeutics has selected Parse’s GigaLab to generate data for its upcomin
Biocytogen Successfully Lists on the STAR Market
December 12, 10:00
Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on t
December 11, 17:50
Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with th
December 11, 16:35
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating pa
Baszucki Group and Cleveland Clinic Neurological Institute expand impact of landmark brain study to
December 11, 15:40
Cleveland Clinic Neurological Institute and Baszucki Group Team Up to Advance Landmark Brain Study with Metabolic Health Markers
Baszucki Group today announced an expanded commitment to the landmark Cleveland Clinic Brain Study (https://my.clevelandclinic.org/departments/neurological/research-innovations/brain-study). Launched
SoluPet Inc. (SoluPet) Announces Strategic Partnership with CHC Healthcare Group (CHC) to Advance Canine Cognitive Health in Asia
December 10, 15:35
SoluPet Inc. (SoluPet) Announces Strategic Partnership with CHC Healthcare Group (CHC) to Advance Canine Cognitive Health in Asia
SoluPet, the data and science-driven pet cognitive health company developing advanced cognitive-aging support for senior dogs, today announced a strategic partnership with CHC, one of Asia’s largest p
December 10, 14:10
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innova
December 09, 16:40
IBMI SNQ and ICHOM Forms Strategic Partnership in Asia, Advancing Patient-centered Healthcare in the Region
The Symbol of National Quality (SNQ), initiated by Taiwan’s Institute for Biotechnology and Medicine Industry (IBMI), has partnered with the International Consortium for Health Outcomes Measurement (I
December 09, 15:20
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 i
Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart
December 09, 15:00
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results o
December 08, 15:12
Galderma Welcomes Increased Equity Investment From L’Oréal
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
December 05, 17:15
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance o
December 05, 15:40
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU
December 05, 14:15
Parse Biosciences Launches Evercode Whole Blood Fixation
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixati
Deanna Kelly, PharmD, BCPP, Live It, Launch It program lead
December 05, 11:20
University of Maryland Launches Innovative Clinician Training Program in Ketogenic Metabolic Therapy for Mental Health
Baszucki Group today announced a partnership with University of Maryland School of Medicine for an innovative training initiative that will build capacity for delivering ketogenic metabolic therapy in
December 05, 11:00
Famenity's Brain Factor-7® Gains Global Momentum as Clinically Validated Ingredient for Cognitive Health
Famenity Co., Ltd. (https://famenity.com/home-en/), a South Korean research and development company specializing in functional ingredients for health supplements, said that its Brain Factor-7® (BF-7®)
December 04, 15:09
Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive o
November 27, 16:00
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
BeOne Medicines Ltd (https://beonemedicines.com/). (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and
November 26, 16:20
With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?
An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (3
November 25, 09:40
Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis
Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, c
November 23, 11:30
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54361159&newsitemid=20251120303213&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
Rajashekar Vasantha (left), Supreet Deshpande (center), and Sahitya Sridhar (right), the founding te
November 21, 14:20
Synthio Labs Raises $5 Million to Build the Voice AI Operating System for Life Sciences Customer Engagement
Synthio Labs, a clinical-grade voice AI company transforming how life sciences organisations engage clinicians and patients, today announced that it has raised $5 million in seed funding. The round wa
The main entrance of K2 MEDITECH headquarters, representing the company’s commitment to innovation a
November 21, 14:07
K2 MEDITECH Sets a New Benchmark in the Global Skin Booster Market
Built on innovative skin-regeneration technology, K2 MEDITECH is rapidly gaining attention in the global beauty and medical aesthetics industries. As a specialized manufacturer of skin boosters, th
November 20, 15:10
Parse Biosciences Announces FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a breakthrough technology that unlocks the full potential of formalin-fixed, paraff
November 20, 15:00
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial e
SPARK Headquarters (SPARK HQ) (Photo: AETOSWire)
November 20, 13:30
Sharjah Emerges as a Global Hub for Medical Innovation and Collaborative R&D
In the United Arab Emirates, where cities like Abu Dhabi (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fu.ae%2Fen%2Fabout-the-uae%2Fthe-seven-emirates%2FAbu-Dhabi&esheet=54359920&n
November 18, 16:06
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This progra
November 18, 15:10
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pert
November 17, 15:50
ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American Society for Dermatolog
November 16, 13:40
Stealth Third Rock Ventures Backed Company Selects Parse Biosciences GigaLab to Build Largest TCR Atlas for Common Autoimmune Disease
Third Rock Ventures and Parse Biosciences today announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs) using Parse Biosciences’ GigaLab platform. The
Bernard Tannoury, President of Benta SAS, and Sohail Zaidi, CEO of Ananda Scientific Inc., signing t
November 16, 13:25
Ananda Scientific and Benta Sign Memorandum on Advancing Treatments for PTSD
Ananda Scientific Inc., a clinical-stage drug development company advancing innovative therapies for high-impact neuropsychiatric disorders, today announced the signing of a Memorandum of Understandin
November 14, 15:10
Galderma Completes Successful Placement of CHF 175 Million Bond
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play de
November 13, 14:50
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma
The U.S. Food and Drug Administration (FDA) has approved the Promega (https://bit.ly/4nUmP66) OncoMate® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatelli
November 13, 10:55
InterSystems Launches HealthShare AI Assistant to Optimize Data Retrieval and Clinical Engagement with Conversational Intelligence
InterSystems (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.intersystems.com%2F&esheet=54356186&newsitemid=20251112864064&lan=en-US&anchor=InterSystems&index=1&md5=a79330a679c0
Qorium is successfully producing sustainable real leather
November 12, 16:25
Qorium Secures €22m Investment to Accelerate Cultivated Leather Commercialisation
Qorium, the Dutch biotechnology company pioneering cultivated leather, today announced it has secured a €22 million investment from Invest-NL and LIOF alongside existing investors Brightlands Venture
November 12, 10:40
Prokarium Appoints Ibs Mahmood as Chief Executive Officer
Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the appointment of Ibs Mahmood as Chief Executive Officer (CEO). Ibs succeeds Kri
Peter Seongwon Hong will serve as the Chief Executive Officer (CEO) of Epis NexLab, in addition to h
November 11, 16:20
Samsung Epis Holdings Announces Establishment of Epis NexLab, a New Subsidiary to Advance Next-Generation Biotechnology Platforms
Samsung Epis Holdings Co., Ltd. today announced the establishment of Epis NexLab Co., Ltd., a new subsidiary that will focus on the development of next-generation biotechnology platforms. Epis NexL
November 10, 15:40
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of
November 10, 10:15
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered
November 09, 09:50
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54353741&newsitemid=20251107689017&lan=en-US&anchor=TSE%3A4
NJ Bio, Inc. now offers translational research services after completing asset purchase and full int
November 07, 11:30
NJ Bio Bridges the Translation Research Gap with the Asset Purchase and Integration of L2P® Services
NJ Bio, Inc., a premier contract research and clinical manufacturing service provider in Princeton, New Jersey has announced the asset purchase and full integration of the research services of L2P Res
Representatives from the Local Content & Government Procurement Authority (LCGPA) and Boston Oncolog
November 07, 10:10
BOSTON ONCOLOGY ARABIA and LOCAL CONTENT & GOVERNMENT PROCUREMENT AUTHORITY Sign Agreement to Localize Advanced Biologic Medicines in Saudi Arabia
In a major step toward advancing pharmaceutical local content and national drug security, BOSTON ONCOLOGY ARABIA and the Local Content & Government Procurement Authority (LCGPA) have signed an agreeme
November 07, 09:50
Merz Aesthetics® Announces New Arms and Abdomen* Indication for Ultherapy PRIME, the Only FDA-Cleared Ultrasound With Real-Time Visualization
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the U.S. Food and Drug Administration (FDA) clearance of Ultherapy PRIME to improve the appearance of skin l
November 05, 16:10
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocaine for augment
November 05, 11:50
Merz Aesthetics® Introduces New BELOTERO® Syringe Offering Greater Precision, Comfort and Ease of Use
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of a new syringe for its category-leading hyaluronic acid (HA) brand BELOTERO®. The new syringe i
November 04, 08:39
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54348492&newsitemid=20251030478402&lan=en-US&anchor=TSE%3A4
Kyung-Ah Kim will serve as the President and Chief Executive Officer (CEO) of Samsung Epis Holdings,
November 03, 11:44
Newly Established Samsung Epis Holdings to Drive Growth for Samsung Bioepis and a New Subsidiary
Samsung Epis Holdings Co., Ltd. today announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). Sams
October 31, 10:40
Novotech Maps Global Growth in Radiopharmaceutical Trials
Novotech, a leading global clinical research organization (CRO) and scientific advisory partner, today released a new white paper detailing the rapid rise of therapeutic radiopharmaceutical research a
October 31, 10:15
Crown Bioscience Achieves Second CLIA Certification of 2025 at Suzhou Laboratory
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced that its Suzhou, China
October 30, 16:51
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54345580&newsitemid=20251029831616&lan=en-US&anc
October 30, 16:30
SS&C Introduces AI Agents to Simplify Financial Services and Healthcare Operations
SS&C Technologies Holdings, Inc. (https://www.ssctech.com/?utm_campaign=SSC2025-Enterprise-Press-Release-1025&utm_medium=pressrelease&utm_source=prnews&utm_content=SSNC-AI-Agents) (Nasdaq: SSNC) today
October 30, 16:20
Swiss Rockets Announces Strategic Exclusive License Acquisition of Cutting-Edge Sequencing Technology from MGI Tech and Complete Genomics
Swiss Rockets, MGI US LLC and Complete Genomics Inc. announced today that they entered into a exclusive license agreement with MGI Tech and Complete Genomics, USA, granting Swiss Rockets a perpetual,
ONEWAYLAB team member demonstrating the company’s flagship device to visitors at the Beautyworld Mid
October 30, 13:52
ONEWAYLAB Expands Global Presence with Cutting-Edge Beauty Tech at Beautyworld Middle East 2025
ONEWAYLAB Co., Ltd. announced its participation in Beautyworld Middle East 2025, one of the world’s leading exhibitions for the beauty and wellness industries, held in Dubai. Certified as an offici
October 30, 09:00
Ferring Pharmaceuticals to Explore Strategic Options for Rebyota®
As part of our ongoing transformation to sharpen our focus, we have decided to explore strategic options for Rebyota® (faecal microbiota, live - jslm). To date, more than five thousand patients suffer
October 29, 10:55
SK pharmteco Achieves Highest-Level My Green Lab Certifications Across Europe and Asia
SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a significant milestone in its commitment to environmental sustainability by earning four My Green La
Professor Nguyen Thanh Liem, Director, Institute of Stem Cell and Genetic Technology Research at Vin
October 28, 15:30
Colorectal, Liver, and Lung Cancer Patients at Vinmec Experience Extended Survival with AIET Cell-Based Immunotherapy - Technology Transferred from Japan
Significantly extended survival and improved quality of life (QoL) for cancer patients achieved through autologous cell-based AIET immunotherapy (https://www.immunotreatment.org/), utilizing patients'
Signing ceremony for the exclusive distribution agreement of the Wholemom artificial insemination so
October 27, 08:00
NURI SCIENCE Expands into Latin American Market through Exclusive Partnership in Paraguay
NURI SCIENCE Inc., a biotechnology company specializing in livestock reproduction technology, has signed an exclusive distribution agreement with Buenos Negocios S.A., a leading agricultural and lives
FACTS Logo
October 26, 11:15
Berry Consultants Releases FACTS 8 Clinical Trial Simulator
Berry Consultants, LLC announced the release of FACTS 8 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.berryconsultants.com%2Fsoftware%2Fchangelog&esheet=54344231&newsitemid=20
October 24, 15:50
AGC Biologics Partners with Rarity PBC to Advance Life-Saving Gene Therapy for “Bubble Baby Disease”
AGC Biologics, your friendly CDMO expert, today announced an agreement with Rarity PBC to provide comprehensive development and Good Manufacturing Practice (GMP) manufacturing for Rarity’s gene therap
October 23, 17:35
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54341613&newsitemid=20251020512177&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
October 23, 16:58
Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first nine months of 2025, delivering record net sales along with strong commerci
October 23, 15:00
Hologic to be Acquired by Blackstone and TPG for up to $79 per Share
Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into a definitive agreement to be acquired by funds managed by Blackstone (“Blackstone”) and TPG in a transaction valued at up to $79 p
Wilmington PharmaTech Continues Expansion with Significant Investment from Curewell Capital
October 23, 14:10
Wilmington PharmaTech Continues Expansion with Significant Investment from Curewell Capital
Wilmington PharmaTech (“WPT”), a U.S.-based specialty contract research, development, and manufacturing organization (CRDMO) focused on custom small molecule API development and manufacturing, today a
HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics
October 23, 11:40
HistoSonics Expands Insurance Coverage for Non-Invasive Liver Tumor Treatment to 45.4 Million Elevance Health Members
HistoSonics (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhistosonics.com%2F&esheet=54343102&newsitemid=20251022130560&lan=en-US&anchor=HistoSonics&index=1&md5=40fd847d883559ad8d0
Rigaku Technology Taiwan Co., Ltd., located in Tai Yuen Hi-Tech Industry Park
October 22, 17:15
Rigaku opens Rigaku Technology Center Taiwan
Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) hereby announces the establishment of Rigaku Technology Taiwan Co., Ltd. (hereinafter “RTTW”), a ne
Ferrer’s pharmaceutical production plant in Sant Cugat del Valles, Barcelona, Spain.
October 22, 15:55
Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule
Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and ph
Baszucki Group 2025 Metabolic Psychiatry Scholar Award Recipients
October 22, 15:15
Baszucki Group Announces Six Recipients of the Metabolic Psychiatry Scholar Award for Emerging Scientific Leaders Advancing Mental Health Innovation
Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award (https://baszuckigroup.com/metabolic-psychiatry-scholar-award/), a new initiative that suppo
October 22, 14:50
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54343084&newsitemid=20251021006409&lan=en-US&anchor=TSE%3A4502%2FNYSE%
Photo credit: IFF
October 22, 11:10
IFF and BASF Announce Strategic Collaboration to Drive Next-Generation Enzyme and Polymer Innovation
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced a strategic collaboration with BASF, one of the world’s largest chemical companies and le
Kyung-Ah Kim, President & CEO of Samsung Bioepis (left) and Zhaoyuan ‘Tony’ Chen, Founder and CEO of
October 21, 09:45
Samsung Bioepis And Phrontline Announce a Global Strategic Partnership to Advance Best-in-Class Antibody-Drug Conjugate Therapeutics for Solid Tumors
Samsung Bioepis Co., Ltd. and Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the companies have entere
October 20, 15:07
Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO
Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of new data from its Phase 1 study of IKS014, a human epidermal growth f
October 19, 16:02
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimul
HistoSonics Announces Oversubscribed $250 Million Growth Financing
October 17, 14:50
HistoSonics Announces Oversubscribed $250 Million Growth Financing
HistoSonics, Inc., the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the closing of an oversubscribed $250 million financing led by its new owners
Credits to Roquette
October 17, 14:15
New Roquette Pharmaceutical Innovation Center to Strengthen Latin America as Collaborative Hub
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for health, nutrition and bio industrial markets, today, celebrates the grand opening of its dedicated Health & Pharm
25 per page50 per page75 per page100 per page